Management

*

Contact Deltenna

Sales Enquiry
WiBE Support

Dr Andrew Fox
Chief Executive Officer

Andrew Fox founded Deltenna in 2002, having previously worked extensively in the fields of radio and antenna design at the prestigious Bell Research Laboratories. Since then he has built a successful business, guiding the development of a series of innovative products and engaging with customers worldwide. Andrew holds a B.Eng (Hons) in communications engineering and a PhD from Leeds Metropolitan University in the field of Microwave Dielectric Resonators and is named as an inventor on more than 16 issued and pending patents.

Alison Aylmer-Kelly
Chief Financial Officer

Alison has over 20 years experience in accounting, starting her career at Grant Thornton, where she spent ten years. In 1998 she joined accounting firm Robson Taylor and progressed to partner, running the firm's Bristol, UK office with responsibility for around 250 corporate clients. She has also provided temporary financial management for clients, assisting directors with the general running of their businesses. She joined Deltenna in 2009 to assist the company with its expansion.

Ian Vance
Non-executive Director

Ian Vance has been in the technology industry for over 35 years, during which time he has been Group VP at Bell Northern Research and Chief Engineer at Nortel Europe. Since leaving Nortel in 1998 he has been active in numerous companies as a non-executive director and consultant. He recently started Spectrum Trading Associates to work on the new opportunities opening up with liberalization of the market for radio frequency allocations.

Dr Tim Hart
Non-executive Director

After obtaining a PhD in microbiology from the University of Surrey, Tim Hart pursued a career in academia before founding Cybersense Biosystems, a company specializing in the development and manufacture of bio-molecular test kits for environmental analysis. Tim was CEO of Cybersense until 2008 and is now CEO of Zyoxel Ltd, a company that is commercializing micro-bioreactor technology to improve drug discovery.